BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BioMarin Pharma (BMRN) Tops Q1 EPS by 39c, Revs Beat; Trims FY Rev Outlook
April 29, 2020 4:03 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.44, $0.39 better than the analyst estimate of $0.05. Revenue for the quarter came in at $502.1 million versus the consensus estimate of $468.77 million.
GUIDANCE:
BioMarin Pharma sees FY2020 revenue of $1.85-1.95 billion, versus prior of... More
